# A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

Source: https://onco.cc/trials/nct07722767/  
OnCo record `nct07722767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CLN-049 run by Cullinan Therapeutics Inc., not yet recruiting.

## Summary

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients is a phase 1 interventional study registered as NCT07722767 by Cullinan Therapeutics Inc., with 90 participants planned, started 2026-10-15. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CLN-049, Azacitidine and Venetoclax.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07722767
- Phase: 1
- Setting: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
- Sponsor: Cullinan Therapeutics Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07722767: https://clinicaltrials.gov/study/NCT07722767

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [CLN-049](https://onco.cc/drugs/cln-049/)
- companies: [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07722767.json